11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Lenoxin Liquidum

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Digoxin

Digoxin

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol. 1997;37:92-100.

  2. LANOXIN (digoxin). DailyMed [www]. US National Library of Medicine. [updated 2018-08-31, cited 2019-02-11].

  3. Lee LS, Chan LN. Evaluation of a sex-based difference in the pharmacokinetics of digoxin. Pharmacotherapy. 2006;26:44-50.

  4. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-11.

  5. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail. 2005;11:83-6.

  6. Lupón J, Urrutia A, González B, Díez C, Altimir S, Albaladejo C et al. Does heart failure therapy differ according to patient sex?. Clin Cardiol. 2007;30:301-5.

  7. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013;34:1481-8.

  8. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8(1):49-58.

  9. Adams KF, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497-504.

  10. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.

  11. Sica DA, Wood M, Hess M. Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations. Congest Heart Fail. 2005;11:163-6.

  12. Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C et al. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017;6(7):1.

  13. Freedman RR, Sabharwal SC, Desai N. Sex differences in peripheral vascular adrenergic receptors. Circ Res. 1987;61:581-5.

  14. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos Int. 2007;18:409-17.

  15. Koski K, Luukinen H, Laippala P, Kivela SL. Physiological factors and medications as predictors of injurious falls by elderly people: a prospective population-based study. Age Ageing. 1996;25:29-38.

  16. Aarnoudse AL, Dieleman JP, Stricker BH. Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf. 2007;30:431-6.

  17. Riesgo A, Sant E, Benito L, Hoyo J, Miró O, Mont L et al. Sex differences in the treatment of patients with atrial fibrillation: population-based study in a local health district. Rev Esp Cardiol. 2011;64:233-6.

  18. Shehab A, Zubaid M, Bhagavathula AS, Rashed WA, Alsheikh-Ali AA, AlMahmeed W et al. Sex differences in management and outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events (Gulf SAFE). PLoS One. 2017;12(5):e0175405.

  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]

  1. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol. 1997;37:92-100.
  2. LANOXIN (digoxin). DailyMed [www]. US National Library of Medicine. [updated 2018-08-31, cited 2019-02-11].
  3. Lee LS, Chan LN. Evaluation of a sex-based difference in the pharmacokinetics of digoxin. Pharmacotherapy. 2006;26:44-50.
  4. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-11.
  5. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail. 2005;11:83-6.
  6. Lupón J, Urrutia A, González B, Díez C, Altimir S, Albaladejo C et al. Does heart failure therapy differ according to patient sex?. Clin Cardiol. 2007;30:301-5.
  7. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013;34:1481-8.
  8. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8(1):49-58.
  9. Adams KF, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497-504.
  10. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.
  11. Sica DA, Wood M, Hess M. Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations. Congest Heart Fail. 2005;11:163-6.
  12. Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C et al. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017;6(7):1.
  13. Freedman RR, Sabharwal SC, Desai N. Sex differences in peripheral vascular adrenergic receptors. Circ Res. 1987;61:581-5.
  14. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos Int. 2007;18:409-17.
  15. Koski K, Luukinen H, Laippala P, Kivela SL. Physiological factors and medications as predictors of injurious falls by elderly people: a prospective population-based study. Age Ageing. 1996;25:29-38.
  16. Aarnoudse AL, Dieleman JP, Stricker BH. Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf. 2007;30:431-6.
  17. Riesgo A, Sant E, Benito L, Hoyo J, Miró O, Mont L et al. Sex differences in the treatment of patients with atrial fibrillation: population-based study in a local health district. Rev Esp Cardiol. 2011;64:233-6.
  18. Shehab A, Zubaid M, Bhagavathula AS, Rashed WA, Alsheikh-Ali AA, AlMahmeed W et al. Sex differences in management and outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events (Gulf SAFE). PLoS One. 2017;12(5):e0175405.
  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]